| 9.1 Relief of overall pain ‐ 200 μg versus 400 μg nafarelin ‐ continuous |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 9.1.1 Pelvic pain ‐ 2 months |
1 |
15 |
Mean Difference (IV, Fixed, 95% CI) |
0.20 [‐1.07, 1.47] |
| 9.1.2 Pelvic pain ‐ 4 months |
1 |
15 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.10 [‐1.07, 0.87] |
| 9.1.3 Pelvic pain ‐ 6 months |
1 |
15 |
Mean Difference (IV, Fixed, 95% CI) |
0.30 [‐0.61, 1.21] |
| 9.2 Relief of overall pain ‐ 400 μg versus 800 μg nafarelin ‐ dichotomous |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9.2.1 Pelvic pain ‐ 6 months |
1 |
77 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.24 [0.71, 2.16] |
| 9.2.2 Dysmenorrhea ‐ 6 months |
1 |
90 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.00 [0.13, 71.74] |
| 9.2.3 Dyspareunia ‐ 6 months |
1 |
57 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.05 [0.49, 2.26] |
| 9.3 Adverse effects ‐ 200 μg versus 400 μg nafarelin ‐ dichotomous |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9.3.1 Vasomotor symptoms (hot flashes or dizziness) ‐ 2 months |
1 |
15 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.44 [0.17, 1.12] |
| 9.3.2 Vasomotor symptoms (hot flashes or dizziness) ‐ 4 months |
1 |
15 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.35 [0.10, 1.27] |
| 9.3.3 Vasomotor symptoms (hot flashes or dizziness) ‐ 6 months |
1 |
15 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.29 [0.08, 1.01] |
| 9.3.4 Rhinitis ‐ 6 months |
1 |
24 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.40 [0.10, 1.67] |
| 9.3.5 Upper respiratory infection ‐ 6 months |
1 |
24 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.20 [0.03, 1.47] |
| 9.3.6 Irregular bleeding ‐ 6 months |
1 |
24 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.71 [0.31, 1.63] |
| 9.4 Adverse effects ‐ 3.75 mg versus 1.88 mg leuprolide acetate ‐ continuous |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 9.4.1 Menopausal symptoms by Kupperman Index ‐ 2 months |
1 |
50 |
Mean Difference (IV, Fixed, 95% CI) |
1.20 [‐3.14, 5.54] |
| 9.4.2 Menopausal symptoms by Kupperman Index ‐ 3 months |
1 |
50 |
Mean Difference (IV, Fixed, 95% CI) |
5.70 [2.12, 9.28] |
| 9.4.3 Menopausal symptoms by Kupperman Index ‐ 4 months |
1 |
50 |
Mean Difference (IV, Fixed, 95% CI) |
9.50 [6.55, 12.45] |
| 9.4.4 Menopausal symptoms by Kupperman Index ‐ 5 months |
1 |
50 |
Mean Difference (IV, Fixed, 95% CI) |
13.20 [10.22, 16.18] |
| 9.5 Improvement of most troublesome symptoms ‐ 400 μg versus 800 μg nafarelin ‐ dichotomous |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9.5.1 Overall improvement ‐ 6 months |
1 |
143 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.78, 1.14] |
